HER2-Positive Gastric Adenocarcinoma — Trials

HER2-Positive Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 6
Ph III recruiting: 2
Growth YoY: —
Industry share: 40%
Top sponsor: Qilu Hospital of Shandong University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04082364	Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY)	completed	Phase 2 / Phase 3	82	MacroGenicsINDUSTRY	9	Jun 8, 2025	clinicaltrials
NCT03602079	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	completed	Phase 1 / Phase 2	49	Klus Pharma Inc.INDUSTRY	1	Aug 3, 2023